Highlights Celgene

Stocks

CELG

Delayed Nasdaq Other stock markets 04:00:00 2019-11-20 pm EST			5-day change	1st Jan Change
108.24 ^USD	+0.10%		-1.97%	+68.89%

23-06-14	Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	CI
21-09-07	Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	CI

Highlights

21-06-21	Celgene Corporation Will Grant Sun Pharmaceutical Industries Limited A License to Celgene's Patents Required to Manufacture and Sell Certain Limited Quantity	CI
19-11-19	Amgen Inc. completed the acquisition of worldwide rights to Otezla from Celgene Corporation.	CI
19-11-19	Celgene Corporation's Equity Buyback announced on June 12, 2013, has expired.	CI
19-11-15	Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes	CI
19-11-15	Celgene Corporation Receives CHMP Positive Opinion for REVLIMID® (lenalidomide) in Combination With Rituximab for the Treatment of Adult Patients With Previously Treated Follicular Lymphoma	CI
19-11-12	Skyhawk Therapeutics Announces Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules That Modulate RNA Splicing	CI
19-10-31	Tranche Update on Celgene Corporation's Equity Buyback Plan announced on June 12, 2013.	CI
19-10-31	Celgene Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2019	CI
19-10-31	Celgene Corporation Provides Earnings Guidance for the Full-Year of 2019	CI
19-10-31	Celgene : Bristol-Myers posts better-than-expected results, Opdivo growth slows	RE
19-09-24	Blade Therapeutics, Inc. acquired ATXCo, Inc. from Bay City Capital LLC, Celgene Corporation and others.	CI
19-09-12	Celgene Announces Phase 3 QUAZAR AML-001 Study of CC-486 as Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Met Primary and Key Secondary Endpoints	CI
19-09-09	Celgene Corporation Presents 13 Scientific Abstracts, Including New Analyses from the Phase 3 Ozanimod Clinical Development Program in Adults	CI
19-08-25	Amgen Inc. entered into an agreement to acquire worldwide rights to Otezla from Celgene Corporation for $13.4 billion.	CI
19-08-16	Celgene Corporation Announces the Approval of U.S. FDA INREBIC as First New Treatment in Nearly Decade for Patients with Myelofibrosis	CI
19-07-30	Tranche Update on Celgene Corporation's Equity Buyback Plan announced on June 12, 2013.	CI
19-07-30	Celgene Corporation Revises Earnings Guidance for 2019 and Reaffirms Earnings Guidance for 2020	CI
19-07-30	Celgene Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2019	CI
19-07-19	Celgene Corporation Announces FDA Approval for the Treatment of Oral Ulcers Associated with Behçet’s Disease	CI
19-06-28	Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes	CI
19-06-06	Celgene Corporation Announces US FDA and EMA Acceptance of Applications for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis	CI
19-06-04	Celgene Corporation Announces Data from Ongoing Studies of Liso-Cel in Patients with Difficult-to-Treat Blood Cancers at ASCO 2019	CI
19-06-03	Celgene Corporation Updates Analysis of Data from the Phase 2 JAKARTA2	CI
19-06-02	Celgene Corporation Presents Data from a Phase 1/2 Clinical Study of Iberdomide in Combination with Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma at ASCO 2019	CI
19-05-28	Celgene Corporation Announces FDA Approves REVLIMID® (Lenalidomide) with Rituximab for the Treatment of Adult Patients with Previously Treated Follicular Lymphoma or Marginal Zone Lymphoma	CI